<DOC>
	<DOCNO>NCT01200134</DOCNO>
	<brief_summary>Background : In malignant glioma , hypoxia associate tumour angiogenesis tumour progression . This multidisciplinary preclinical clinical project aim validate use 18F-FMISO hypoxic marker diagnosis , treatment follow-up malignant glioma . Indeed , non-invasive method imagery Positron Emission Tomography ( PET ) biological method ( surgical resection ) detect endogenous expression factor induce hypoxia would allow identify hypoxic area . Identifying , accuracy , hypoxic area could allow clinician evaluate response anti-angiogenic agent ( preliminary validation preclinical project ) optimize combination anti-VEGF treatment conventional therapeutic approach ( radiotherapy , chemotherapy molecule ) . Research project : This research project include 3 step : first investigator establish 18F-FMISO production technique clinical application CYCERON PET center . The second step consist preclinical validation 18F-FMISO hypoxic marker powerful tool evaluate therapeutical efficiency anti-angiogenic treatment ( sutent ) experimental rat glioma . The third step clinical trial HypOnco . This research proposal aim develop use non invasive imaging method ( 18F-FMISO PET ) biological method ( surgical resection ) detect hypoxic ( HIF1 HIF2 ) angiogenic ( VEGF EPO ) region different malignant glioma different degree vascularization ( 15 patient grade III glioma 15 patient grade IV glioblastoma ) . Within patient 18F-FMISO hypoxic index perform . A magnetic resonance image examination ( MRI ) include perfusion sequence MR spectroscopy also assess patient . Following image protocol , surgical resection perform allow u study expression endogenous factor induce hypoxia angiogenic factor real time RT-PCR immunohistochemistry . The data obtain enable u establish : - hypoxic index ( 18F-FMISO PET ) . - index hypoxic factor expression ( HIFs ) - angiogenic index ( VEGF , EPO , vascular marker ) The investigator characterize link data also follow parameter : - clinical ( age , Karnofsky performance status , survival ) - MR parameter include perfusion spectroscopy - histological ( necrosis , cellular proliferation , atypical cell abnormality , vascularization ) . Expected result clinical advantage - To establish 18F-FMISO production technique - To propose 18F-FMISO non-invasive marker efficacy antiangiogenic treatment preclinical study . - To define relationship 18F-FMISO uptake tumour grade , patient survival , tumour recurrence , expression hypoxic angiogenic factor tumour vascularisation . - To provide hypoxic index cerebral tumours 18F-FMISO PET , allow diagnosis prognosis improvement optimal treatment orientation strategy . In field clinical application , tool allow : - Optimize radiotherapy treatment identify accuracy , use 18F-FMISO PET , hypoxic area also radio resistant . - Evaluate antiangiogenic therapy efficacy</brief_summary>
	<brief_title>HYPONCO - Hypoxia Brain Tumors</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Misonidazole</mesh_term>
	<criteria>adult age &gt; = 18 year KPS &gt; = 70 % must understand ability sign inform consent document male nonpregnant nonlactating female Patients fertile must agree use effective method contraception participation study follow laboratory result : absolute neutrophil count &gt; = 1500 cells/µl , platelet count &gt; = 100,000 cells/µl , SGOT &lt; = 2.5 x ULN , serum creatinine &lt; = 1.5 x ULN contraindication surgery concomitant radio , chemo , immunotherapy know diagnosis Human Immunodeficiency Virus ( HIV ) infection patient hepatitis B C diabetic patient patient kidney liver deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>glioma patient : anaplasic glioma ( grade III ) GBM ( grade IV )</keyword>
</DOC>